Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)

NCT01700192 is registered in ClinicalTrials.gov with ALK-Abelló A/S as lead sponsor.

NCT NCT01700192
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01700192 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Lead sponsor
ALK-Abelló A/S
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2013
Completion date
April 30, 2015
Enrollment
1,482 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

rhinitis, allergic, nonseasonal, rhinitis, allergic, perennial